<DOC>
	<DOCNO>NCT01515345</DOCNO>
	<brief_summary>The purpose study determine efficacy safety routine individualize antiplatelet therapy coronary stent implantation evaluate `` on-treatment '' platelet reactivity Multiple Electrode Aggregometry ( MEA , Multiplate® Analyzer ) .</brief_summary>
	<brief_title>Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI Registry</brief_title>
	<detailed_description>Depending clinical presentation patient treat accord standard operating procedure department . The early , 12 hour initial clopidogrel-loading dose ( 600mg ) '' on-treatment '' platelet reactivity determine Multiple Electrode Aggregometry ( MEA , Multiplate® Analyzer ) , point care assay . In case high residual platelet reactivity ( i.e . ≥ 50U ) , patient switch accord therapeutic algorithm either prasugrel ( Efient® ) , case contraindication ( i.e . stroke ) ticagrelor ( Brilique® ) , case contraindication ( intracranial hemorrhage ) reload clopidogrel .</detailed_description>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>consecutive PCI patient stent implantation institution pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>clopidogrel-nonresponder</keyword>
	<keyword>stent thrombosis</keyword>
</DOC>